MX2024000636A - Inhibicion genica y tratamiento mediante secuencia antisentido (aso). - Google Patents
Inhibicion genica y tratamiento mediante secuencia antisentido (aso).Info
- Publication number
- MX2024000636A MX2024000636A MX2024000636A MX2024000636A MX2024000636A MX 2024000636 A MX2024000636 A MX 2024000636A MX 2024000636 A MX2024000636 A MX 2024000636A MX 2024000636 A MX2024000636 A MX 2024000636A MX 2024000636 A MX2024000636 A MX 2024000636A
- Authority
- MX
- Mexico
- Prior art keywords
- aso
- antisense oligonucleotide
- treatment
- gene inhibition
- asos
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222336P | 2021-07-15 | 2021-07-15 | |
| US202163224362P | 2021-07-21 | 2021-07-21 | |
| PCT/US2022/073668 WO2023288240A1 (en) | 2021-07-15 | 2022-07-13 | Antisense oligonucleotide (aso) gene inhibition and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000636A true MX2024000636A (es) | 2024-02-06 |
Family
ID=82850241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000636A MX2024000636A (es) | 2021-07-15 | 2022-07-13 | Inhibicion genica y tratamiento mediante secuencia antisentido (aso). |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4370133A1 (https=) |
| JP (1) | JP2024525837A (https=) |
| KR (1) | KR20240037996A (https=) |
| AU (1) | AU2022312494A1 (https=) |
| CA (1) | CA3224471A1 (https=) |
| IL (1) | IL309813A (https=) |
| MX (1) | MX2024000636A (https=) |
| WO (1) | WO2023288240A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121039279A (zh) * | 2023-05-05 | 2025-11-28 | 万达制药公司 | 反义寡核苷酸(aso)基因抑制和治疗 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014161046A1 (en) * | 2013-04-04 | 2014-10-09 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating diseases characterized by excessive wnt signalling |
| WO2017214463A1 (en) * | 2016-06-09 | 2017-12-14 | The Regents Of The University Of California | Compositions and methods for treating cancer and biomarkers to detect cancer stem cell reprogramming and progression |
-
2022
- 2022-07-13 IL IL309813A patent/IL309813A/en unknown
- 2022-07-13 JP JP2024502210A patent/JP2024525837A/ja active Pending
- 2022-07-13 MX MX2024000636A patent/MX2024000636A/es unknown
- 2022-07-13 CA CA3224471A patent/CA3224471A1/en active Pending
- 2022-07-13 AU AU2022312494A patent/AU2022312494A1/en active Pending
- 2022-07-13 EP EP22753948.3A patent/EP4370133A1/en active Pending
- 2022-07-13 KR KR1020247004273A patent/KR20240037996A/ko active Pending
- 2022-07-13 WO PCT/US2022/073668 patent/WO2023288240A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022312494A9 (en) | 2024-01-25 |
| WO2023288240A8 (en) | 2023-12-14 |
| AU2022312494A1 (en) | 2024-01-18 |
| JP2024525837A (ja) | 2024-07-12 |
| EP4370133A1 (en) | 2024-05-22 |
| KR20240037996A (ko) | 2024-03-22 |
| CA3224471A1 (en) | 2023-01-19 |
| WO2023288240A1 (en) | 2023-01-19 |
| IL309813A (en) | 2024-02-01 |
| WO2023288240A9 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2560107T3 (es) | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF | |
| JP7851349B2 (ja) | Scn1a脳症の治療のためのscn2aを標的とするアンチセンスオリゴヌクレオチド | |
| CA2730203C (en) | Complement antagonists and uses thereof | |
| JP6250078B2 (ja) | 真核細胞におけるエキソンスキッピングの誘導 | |
| Li et al. | MiR-30b-5p attenuates oxaliplatin-induced peripheral neuropathic pain through the voltage-gated sodium channel Nav1. 6 in rats | |
| KR101166214B1 (ko) | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법 | |
| KR20220104677A (ko) | 스플라이싱 및 단백질 발현을 조절하기 위한 조성물 및 방법 | |
| KR101142080B1 (ko) | 전립선암 및 다른 암의 치료 방법 및 조성물 | |
| US20180153919A1 (en) | Organic compositions to treat kras-related diseases | |
| ATE280590T1 (de) | Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen | |
| JP2021535204A5 (https=) | ||
| CA2858576A1 (en) | Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease | |
| JP2023521094A5 (https=) | ||
| MX2025003172A (es) | Agente de arni modificado especifico y composicion | |
| JP2022031642A (ja) | アンチセンスオリゴヌクレオチド | |
| MX2024000636A (es) | Inhibicion genica y tratamiento mediante secuencia antisentido (aso). | |
| CA2515484A1 (en) | Modulation of insulin like growth factor i receptor expression | |
| MX2025013103A (es) | Inhibicion y tratamiento del gen de oligonucleotidos antisentido (aso). | |
| TW202529779A (zh) | 用於抑制突觸核蛋白α(SNCA)基因表達的組合物和方法 | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| WO2024263791A1 (en) | Antisense oligonucleotides targeting mir-34a-5p and methods of use thereof | |
| WO2011105902A2 (en) | Antagonists of complement component 8-beta (c8-beta) and uses thereof | |
| WO2018152223A1 (en) | Methods of treating angiogenesis-related disorders using jnk3 inhibitors | |
| WO2011105901A2 (en) | Antagonists of complement component 9 (c9) and uses thereof | |
| WO2011105900A2 (en) | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |